
Tamara L. Kalir
- ASSOCIATE PROFESSOR Pathology
- ASSISTANT PROFESSOR Obstetrics, Gynecology and Reproductive Science
Print Profile
Specialty
Certifications
Anatomic Pathology
Clinical Focus
- Anal Intraepithelial Lesions
- Cervical Cancer
- Cervical Intraepithelial Neoplasia
- Cervicitis
- Endometrial Cancer
- Endometrial Hyperplasia
- Endometrial Intraepithelial Neoplasia
- Endometriosis
- Fallopian Tube Carcinoma
- Genital Warts
- Metastatic Disease To The Ovaries
- Ovarian Cancer
- Ovarian Functional Cysts
- Pseudomyxoma Ovarii And Peritonei
- Salpingitis
- Uterine Cancer
- Uterine Sarcoma
- Vaginal Cancer
- Vaginal Intraepithelial Neoplasia
- Vulvar Cancer
- Vulvar Intraepithelial Neoplasia
Education
MD, University of California, San Diego
Ph.D., Georgetown University
Cell BiologyM.D., University of California School of Medicine
Mount Sinai School of Medicine
PathologyMount Sinai School of Medicine
Gynecologic PathologyResidency, Pathology
Mount Sinai HospitalFellowship, Gynecology Pathology
Mount Sinai Hospital
Biography
- Dr. Tamara Kalir is jointly appointed in the Departments of Pathology, and Obstetrics, Gynecology & Reproductive Science. She is the Director of the Division of Gynecologic Pathology, and Director of the Sexual & Reproductive Health & Diseases Course for 2nd year medical students. Her research interest is gynecologic neoplasia, with emphasis on pathobiology of ovarian cancer.
Research
Our main research interest is the pathogenesis of ovarian cancer. Studies ranged from morphologic and immunohistochemical comparisons of endometriosis with atypical endometriosis and associated neoplasia, to investigating the nuclear membrane pore complex in ovarian cancer, via electron microscopic and molecular biologic techniques. These exciting studies are ongoing and students are encouraged to participate.Publications
Burstein DE, Idrees MT, Li G, Wu M, Kalir T. Immunohistochemical detection of the X-linked inhibitor of apoptosis protein (XIAP) in cervical squamous intraepithelial neoplasia and squamous carcinoma. Ann Diagn Pathol 2008 Apr; 12(2): 85-89.
Teixeira MS, Camacho-Vanegas O, Fernandez Y, Narla G, DiFeo A, Lee B, Kalir T, Friedman SL, Schlecht NF, Genden EM, Urken M, Brandwein-Gensler M, Martignetti JA. KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma. Int J Cancer 2007 Nov; 121(9): 1976-7983.
Idrees M, Zakashansky K, Kalir T. Xanthogranulomatous salpingitis associated with fallopian tube mucosal endometriosis: a clue to pathogenesis. Ann Diagn Pathol 2007 Apr; 11(2): 117-121.
Copperman AB, Wells V, Luna M, Kalir T, Sandler B, Mukherjee T. Presence of hydrosalpinx correlated to endometrial inflammatory response in vivo. Fertil Steril 2006 Oct; 86(4): 972-976.
Nagarsheth NP, Harrison M, Kalir T, Rahaman J, . Malignant pericardial effusion with cardiac tamponade in a patient with metastatic vaginal adenocarcinoma. Int J Gynecol Cancer 2006 May-une; 16(3): 1458-1461.
DeFeo A, Naria G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL, Kalir T, Yao S, Levine A, Birrer MJ, Bonome T, Friedman SL, Buller RE, Martignetti JA, . Roles of KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res 2006 June; 12(12): 3730-3739.
Schlager A, Altchek A, Kalir T, Deligdisch L, Weber KJ, . Mesenteric fibromatosis masquerading as an ovarian neoplasm twenty years after Chernobyl radiation exposure. Gynecol Oncol 2006 Sep; 102(3): 587-589.
Kalir T, Simsir A, Demopoulos HB, Demopoulos RI. Obstacles to the early detection of endocervical adenocarcinoma. Int J Gynecol Pathol 2005 Oct; 24(4): 399-403.
Nagarsheth NP, Kalir T, Rahaman J. Post-transplant lymphoproliferative disorder of the cervix. Gynecol Oncol 2005 Apr; 97(1): 271-275.
Kalir T, Rahaman J, Hagopian G, Demopoulos R, Cohen C, Burstein DE. Immunohistochemical detection of glucose transporter GLUT1 in benign and malignant fallopian tube epithelia, with comparison to ovarian carcinomas. Arch Pathol Lab Med 2005 May; 129(5): 651-654.
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Kalir did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Annenberg Building Floor 15 Floor Room Swing Room
1468 Madison Avenue
New York, NY 10029
Fax: 212-289-2899


